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Research Progress of DNA
Methylation in Thyroid Cancer
Zhu Gaohong and Xie Lijun
Abstract
We have summarized increasing data from all kinds of experiment results of
papers in recent years, which are associated with tumor suppressor genes, onco-
genes, and thyroid-specific genes and attempt to elucidate the importance of epige-
netic modifications and the mechanisms of aberrant DNA methylation in thyroid
cancer in this review. The results showed that current articles have revealed the
importance of epigenetic modifications and the different types of mechanisms in
thyroid cancer. The mechanisms of DNA methylation related to thyroid cancer
demonstrate that acquired epigenetic abnormalities together with genetic changes
play an important role in alteration of gene expression patterns. Aberrant DNA
methylation has been well known in the CpG regions. Among the genes identified,
we have shown the status of DNA promoter methylation in papillary, follicular,
medullary, and anaplastic thyroid cancer. It suggested that thyroid cancer subtypes
present differential promoter methylation signatures, which will encourage poten-
tial thyroid cancer detection in its early stages, assessment of prognosis, and
targeted cancer treatment.
Keywords: thyroid carcinoma, DNA methylation, epigenetic inheritance, tumor
suppressor genes, oncogene genes, thyroid-specific genes
1. Introduction
Thyroid cancer is the most frequent endocrine neoplasia. The National Cancer
Institute estimated that there would be 44,670 new cases of thyroid cancer (TC)
with 1690 deaths in 2010, and with an overall estimate of 56,870 new cases by 2017,
and its incidence has been increasing in recent decades. Compared with other adult
cancers, TC tends to occur in younger people between the ages of 20 and 60. It is
three times more common in women than men [1] and has the fastest rising
incidence rates in women and the second fastest in men with an annual percentage
change of approximately 5%, making TC the sixth most common cancer in women
[2]. There are four main types of which papillary and follicular (PTC, FTC) types
together account for >90% followed by medullary thyroid cancers (MTC) with
3–5% and anaplastic carcinomas (ATC) making up <3% [3]. Reasons for this trend
have been attributed to improvement in imaging (ultrasound technology) that is
allowing the identification of ever smaller thyroid nodules. However, with this gain
in detection, determining which benign nodules (adenomas) will progress to cancer
cannot be determined on the basis of histology alone, underscoring the need for
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genetic markers of early detection for TC. Recently, epigenetic alterations have
been shown to play a role in the development and progression of thyroid cancer.
With the deepening of tumor research, it has been gradually found that epige-
netics plays an important role in the occurrence and development of tumors.
Mechanisms of epigenetics include, but are not limited to, DNA methylation
(methylating of ciliary carbon at position 5), posttranslation modification of his-
tone, chromatin remodeling (structural change), gene imprinting, RNA interfer-
ence (noncoding RNA or gene silencing), etc. The epigenetic mechanisms of tumor
cells have lost a fine regulation, and the breakdown of epigenetic patterns will lead
to tumor phenotype expression. These mechanisms have been reviewed elsewhere,
and here we will focus on DNA methylation in thyroid cancer.
DNA methylation is an important epigenetic change, which is persistent and
hereditary. The methylation of promoter CpG can regulate gene expression and
maintain chromosome integrity and DNA recombination. Based on 789 samples
from the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA)
databases, the five-CpG signature could provide a novel biomarker with useful
applications in thyroid cancer (PTC, FTC, ATC, and MTC) diagnosis and the
diagnostic score formula on the condition of DNA methylation data [4]. However,
the methylation pattern is unstable and can be reversed by small molecules and
endogenous enzymes, leading to dedifferentiation and tumor heterogeneity.
Abnormal DNA methylation, including a decrease in the overall methylation level
of the genome, was accompanied by hypermethylation in some gene promoter
regions. The hypermethylation of tumor suppressor gene promoter can reduce its
expression, while the hypomethylation of tumor suppressor gene promoter can
increase its expression, leading to tumorigenesis [5–8]. The following will describe
the state of aberrant DNA methylation in different thyroid cancers.
2. DNA methylation in PTC
RET/PTC rearrangement and mutations in Ras and BRAF genes often occur in
papillary thyroid carcinoma (PTC) [9]. In addition, many methylation of cancer
suppressor genes are associated with BRAF gene mutations, such as Ras-association
domain family 1A (RASSF1A), solute carrier family 5 member 8 gene (SLC5A8),
retinoic acid receptor β2 (RARβ2), tissue inhibitor of metalloproteinase3 (TIMP3),
phosphatase and tensin homolog deleted on chromosome ten (PTEN),
metallothionein 1G (MT1G), ataxia-telangiectasia mutated (ATM), E-cadherin
(ECAD), death-associated protein kinase (DAPK), multiple tumor suppressor 1
(MTS1 or P16), and mut-L homolog 1 (MLH1). Mutations of TSHR gene are not
common in thyroid cancer, but high methylation and low expression of TSHR gene
often occur. Recent studies have found that thyroid-specific genes (thyroid-
stimulating hormone receptor and sodium/iodide symporter (TSHR and NIS),
thyroid transcription factor-1 (TTF-1)) play an important role in occurrence and
development of PTC. This part summarizes the related research on methylation
genes in PTC in recent years (see Table 1).
2.1 DNA methylation of cancer suppressor genes in PTC
2.1.1 Ras association domain family 1 (RASSF1A)
RASSF1A is a member of Ras superfamily, which is located at chromosome 3
(exactly on 3p21.3). Hypermethylation of CpG islands in the RASSF1A promoter
region contributes to epigenetic inactivation. It is a tumor suppressor gene widely
2
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Sample sources Main method Related
gene
Methylation
(high/low)
Related gene
expression
(high/low)
BRAF
mutation
(+/)
Cell
pathway
Function References
Tumor suppressor genes
Patient tissue, normal
people tissue
Western blotting analyses, RT-QPCR,
fluorescent analysis
RASSF1A High Low + MAPK Stabilize the microtubules [12, 13]
SLC5A8 High Low + Sodium transporter [17]
RARβ2 High Low + Negative regulation of cell cycle [20]
TIMP3 High Low + Inhibitor of metalloproteinase [23]
Patient tissue, normal
people tissue
Methylation-specific PCR, RT-QPCR PTEN High Low + PI3K/Akt Inhibit PI3K/Akt pathway [26]
MT1G High Low + Metallothionein [28]
ATM High Low + Regulate cell cycle [29]
Patient tissue, normal
people tissue
Database query and retrospective
medical chart, RT-PCR
ECAD High Low + Wnt/β-
catenin
Mediate the adhesion of cells [8]
Thyroid-specific genes
Patient tissue, normal
people tissue
Western blotting analyses, RT-QPCR NIS High Low + TSHR/
cAMP
Sodium transporter [36]
TSHR High Low + Thyrotropin receptor [37]
TTF-1 High Low + Inhibit the pro-adipogenic
response to pioglitazone
[40]
Other potential genes
Patient tissue, thyroid
cancer cell line
Western blotting analyses, RT-QPCR,
bisulfite sequencing, and
methylation-specific PCR
RASSF10 High – – Others Inhibit cell proliferation [42]
14-3-3σ High – – Cell cycle regulation [45]
RIZ1 High – – Epigenetic mechanisms [44]
DACT2 High – – Inhibiting Wnt signaling [45]
Table 1.
Aberrant methylated genes in PTC.
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expressed in various normal organs but is often deleted in tumors. It is speculated
that BRAFV600E gene mutation in PTC regulated the RASSF1A-MST1-FoxO3 sig-
naling pathway, which led to RASSF1A hypomethylation and affected the malig-
nant degree of thyroid cancer. It is found that the methylation rate of RASSF1A in
thyroid cancer is 15–75% [10]. Studies indicated RASSF1A methylation differed in
PTC compared with normal thyroid and was correlated with extracapsular invasion
inversely. It suggested that RASSF1A has a potential role as a molecular marker for
characterization of PTC histopathology [11–15]. It is shown that hypermethylation
of RASSF1A promoter region is 20–32% in PTC. Hypermethylation of RASSF1A in
PTC was related to the multifocal and extracapsular invasion of tumors [16].
2.1.2 Solute carrier gene family 5A, member 8 (SLC5A8)
SLC5A8 is a passive iodine transporter located in the parietal membrane of
thyroid follicular cells. SLC5A8 is not regulated by thyrotropin in normal thyroid
tissues but methylated in thyroid tumors. Hypermethylation often occurred in the
first exon of CpG islands in SLC5A8, which results in gene silencing and restoring
expression inhibiting cancer cell growth. It has been pointed out that SLC5A8
was an anti-oncogene of colon cancer [17]. SLC5A8 was also frequently
hypermethylated in thyroid cancer. Its function is unclear nowadays, but its
hypermethylation might play a key role in the occurrence of thyroid cancer [18].
Studies revealed that SLC5A8 gene was highly methylated in typical PTC (90%) and
only 20% in other types of PTC. In addition, low expression of SLC5A8 was also
associated with BRAF T1796A, suggesting that SLC5A8 methylation may be impor-
tant in MAPK pathway [19].
2.1.3 Retinoic acid receptor beta2
RARβ2 is a type of nuclear receptor that is activated by both all-trans retinoic
acid and 9-cis retinoic acid, which has been shown to function as a tumor suppres-
sor gene in different types of human tumors. It has been found that RARβ2 expres-
sion was decreased or deleted in tumors. It meant that RARβ2 inactivation was
related to tumorigenesis. In the treatment of metastasis and recurrence of thyroid
cancer, retinoic acid therapy could restore the iodine uptake ability of metastasis
and then improved the efficacy of 131-I radiotherapy. Researches indicated that the
methylation rate of RARβ2 in thyroid cancer was 14%, higher than that in normal
thyroid tissues (7%). RARβ2 gene methylation was associated with BRAF gene
mutation in Wnt/beta catenin pathway [20]. Studies found there was RARβ2 gene
hypermethylation in thyroid cancer cell lines. And after treatment with 5-
azacytidine, RARβ2 expression was significantly increased, and the growth of
tumors was inhibited, while the inhibition still existed after removing 5-azacytidine.
RARβ2 gene methylation took part in tumorigenesis and development in PTC [21].
2.1.4 Tissue inhibitor of metalloproteinases-3 (TIMP3)
TIMP3 can bind to matrix metalloproteinases (MMPs), inhibiting the activity of
MMPs effectively [20, 22]. Methylation of TIMP3 promoter has been demonstrated
in many malignant tumors. It is often associated with growth, invasion, and lymph
node metastasis of malignant tumors. It is pointed out that BRAF mutation caused
low expression of TIMP3 in PTC, which could cause invasion and progression of
tumors. It was found that 38% of TIMP3 are hypermethylated in PTC [23].
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2.1.5 Phosphatase and tensin homolog deleted on chromosome 10 (PTEN)
The PTEN gene is located on chromosome 10 (especially on the region of
10q23), which could encode a specific phosphatidylinositol triphosphate 3 dephos-
phorylation and inhibit the activation of PI3K/Akt signaling pathway. PTEN
expression alteration is crucial to the pathogenesis of cancer and other diseases. Low
level of PTEN caused by homozygous deletions, frameshift, nonsense mutations or
hypermethylation, or PTEN protein destability occurs frequently in various human
cancers [24, 25]. It was shown that PTEN gene expression was low in thyroid
cancer. One study found the methylation status of PTEN in FA, FTC, and PTC. The
results indicated that PTEN methylation level was gradually increased in PTC
(45.7%), FA (83.3%), and FTC (85.7%). PTEN methylation was related to muta-
tions genes in PI3K/Akt signaling pathway, such as PIK3CA and Ras genes,
suggesting that PTEN methylation and PI3K/Akt signaling pathway played an
important role in the process of occurrence and development in PTC [26].
2.1.6 Metallothionein 1G (MT1G)
MT1G, a member of the metallothionein family, is a highly conserved cysteine-
rich small molecule, which is mainly involved in metal-related transport. MT1G
exists in normal cells; it can regulate and maintain intracellular metal ion balance,
cell proliferation, and apoptosis. MT1G promoter methylation is associated with
decreasing gene expression, but not complete abrogation. Studies have shown that
MT1G gene has abnormal methylation in thyroid cancer, liver cancer, colon cancer,
and prostate cancer. It is confirmed that restoring MT1G gene expression could
inhibit tumors growth in vivo and in vitro, suggesting that MT1G gene has antican-
cer effect [27]. It is shown that MT1G gene was abnormally methylated in thyroid
cancer (30.3% in malignant tumors and 18.8% in benign tumors). Its expression was
significantly decreased, and that methylation of MT1G gene was associated with its
low expression. Further studies suggested that restoring MT1G gene expression
could inhibit the growth and infiltration of PTC and induced cell cycle inhibition
and apoptosis. The mechanism may inhibit PI3K/AKT pathway. In addition,
hypermethylation of MT1G was also associated with lymph node metastasis [28].
2.1.7 Ataxia-telangiectasia mutated
ATM belongs to the PI3/PI4 enzyme family. Although there is emerging evi-
dence for a role of ATM in promoting tumorigenesis, ATM signaling provides a
barrier to activated oncogenes and tumor progression, rather than promoting can-
cer early in tumorigenesis. ATM is ubiquitous in human and other higher animal
tissues and cells, such as testicular tissue. And a study showed that ATM was
hypermethylated in PTC (50%) and 0% in normal thyroid tissue [29].
2.1.8 E-cadherin
ECAD is a family of transmembrane glycoproteins responsible for calcium-
dependent cell adhesion. It is the key structural components of adherens junctions.
It is reported that ECAD may also act as a gene transcriptional regulator. Two main
mechanisms including hypermethylation of the promoter and microRNA imbalance
have been widely studied under the ECAD regulation in head and neck tumors. The
methylation of ECAD promoter region was accounted for 39.3% in PTC, and ECAD
expression decreased in the early stage of tumorigenesis. The experiment data
showed that methylation level of ECAD in thyroid cancer increased to 56% (18/32)
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and 0% (0/27) in normal thyroid tissue. Further studies found that there was no
significant correlation between ECAD methylation and T stage of lymph node
metastasis in thyroid cancer. After 2.6 years of follow-up, the recurrence of thyroid
cancer associated with ECAD methylation has no correlation [8].
2.1.9 Death-associated protein kinase
DAPK is a calmodulin-regulated ATK, which has an important role in the pro-
cess of apoptosis. DAPK mechanism is largely due to promoter hypermethylation,
leading to gene silencing. DAPK is ubiquitous in normal tissues. When the promoter
of DAPK is methylated, it will cause an abnormal gene expression. Abnormal
expression of DAPK can hinder the normal process of apoptosis and bring about
tumorigenesis. And its low expression or deletion is one of the important mecha-
nisms of cell carcinogenesis. It has been found that methylation of CpG island in the
promoter region in DAPK is an important reason for expression silencing. The loss
of DAPK protein in sporadic colorectal cancer is caused by the promoter
hypermethylation. It existed in very small tumors. Therefore, the loss of DAPK gene
plays an important role in the early stage of tumor formation. It is reported that
DAPK promoter methylation accounts for 51% in PTC and abnormal methylation
and DAPK gene silencing existed in many kinds of cancer cells [30]. It is pointed out
that the high methylation level of DAPK gene was associated with tumor size and
multiple lesions [31].
2.1.10 Multiple tumor suppressor 1 (MTS1 or P16)
MTS1 is hereafter called p16. It is an anti-oncogene in many tumors. The 50-CpG
fragment in the promoter region of P16 gene is the most susceptible to methylation,
inhibiting its expression products. Abnormal expression of P16 gene can over-
activate cyclin-dependent protein kinase 4 and stimulate abnormal cell prolifera-
tion, leading to tumorigenesis. Aberrant methylation of promoter region in P16
gene is the main cause for P16 gene inactivation [32]. Some scholars reported that
the P16 gene was hypermethylated (35.9%) in PTC [33].
2.1.11 Mut-L homolog 1
MLH1 is one of the DNA mismatch repair genes located on the 3p21 region in
chromosome 3. A correlation between MLH1 promoter methylation, specifically the
‘C’ region stops in MLH1 protein formation, can prevent the normal activation of
DNA repair gene. Low expression of MLH1 gene was associated with BRAFV600E
mutation and RET/PTC rearrangement. Hypermethylation of MLH1 promoter was
found in colon cancer as well. A study indicated that abnormal methylation of
MLH1 was significantly correlated with lymph node metastasis of PTC, suggesting
that MLH1 might be a molecular marker of lymph node metastasis in PTC [34].
Another study found that there were abnormal methylation and low expression of
MLH1 in thyroid cancer and MLH1 expression is associated with BRAF, IDH1, and
NRAS gene mutations [35].
2.2 DNA methylation of thyroid-specific genes in PTC
2.2.1 Thyroid-stimulating hormone receptor and sodium/iodide symporter
On the other hand, methylation of thyroid-specific genes is also one of the
causes for occurrence and development of PTC. Thyroid-specific genes mainly
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include TSHR, NIS, thyroglobulin (Tg), and thyroid peroxidase (TPO), which
participate in thyroid iodine uptake and maintenance of normal thyroid function.
Under normal conditions, TSH stimulates TSHR on thyroid follicular epithelial
cells and activates NIS to ingest iodine into cells. TSH is produced by the pituitary
thyrotrophs and stimulates thyroid functions using TSHR. The iodine ingested
synthesizes thyroid hormones catalyzed by TPO and is stored in Tg. It is found that
abnormal expression of these molecules is related to iodine metabolism in PTC.
Studies have shown that the expression of TSHR, NIS, Tg, and TPO with BRAF
mutated in thyroid cancer is decreased [36]. In PTC, both TSHR and NIS are
abnormally methylated, and their expression is decreased. Low expression of TSHR
and NIS may be related to the occurrence and development of tumors. It also
reduces the uptake of iodine capacity in tumor cells. Scholars found TSHR and
NIS become an important cause for PTC in 131-I radiotherapy [37, 38]. In human
and rabbit thyroid cancer cells, BRAFV600E mutant, a carcinogenic homolog of
murine sarcomatous virulent bacterium, could cause activation of BRAF/MEK/
MAPK signaling pathway and expression silencing of thyroid-specific genes
including TPO, Tg, TSHR, and NIS. At last, it resulted in the reduction of iodine
uptake in PTC.
2.2.2 Thyroid transcription factor-1
TTF-1 is known as thyroid-specific enhancer-binding protein (T/EBP). It is a
transcription factor with homologous domains in the thyroid, lung, and central
nervous system. TTF-1 gene is located in region 14q13.3 on chromosome 14. It is
comprised of three exons and two introns. Under physiological conditions, TTF-1 is
stable positive in thyroid tissue. TTF-1 can regulate the expression of thyroid-
related genes such as TG, TPO, TSHR, and NIS. Thus it acts a pivotal part in
regulating growth, development, and function of thyroid. It showed hNIS mRNA
expression loss might be related to methylation of thyroid-specific transcription
factor genes. Abnormal methylation caused loss of transcription factor expression
with indirect loss of hNIS mRNA expression through the KAT-5 and KAT-10
responses to 5-azacytidine treatment with acquisition of parallel TTF-1 and hNIS
mRNA expression. It was found that insufficient expression of TTF-1 and Pax-8
may result in the decrease of activity of thyroglobulin gene promoter in thyroid
cancer cells. Some confirmed that TTF-1 gene was expressed lowly in thyroid
cancer [39]. Other researchers studied the methylation status of TTF-1 in thyroid
cancer and found that TTF-1 gene was highly methylated and lowly expressed in
thyroid cancer cell lines, but not in normal thyroid [40].
2.3 DNA methylation of oncogene gene in PTC
At present, BRAF gene mutation has been found in melanoma, ovarian serous
tumor, colorectal cancer, glioma, liver cancer, and leukemia. A large number of
studies also showed that BRAF gene mutation in PTC is closely related to methyla-
tion of tumor suppressor. BRAF gene is an important transducer for Ras/Raf/MEK/
ERK/MAPK pathways. About 90% of T1799A point mutation in BRAFV600E hap-
pen in PTC, which can increase BRAF activity. The BRAF gene plays its biological
role by activating MEK/ERK signaling pathway. The result showed that PTC with
BRAF gene mutation had strong tissue invasiveness and was easy to infiltrate tissues
around thyroid gland [41]. Methylation of TIMP3 gene, SLC5A8 gene, and DAPK
gene, which are tumor suppressor genes, are related to BRAF gene mutation and
PTC invasion. The overexpression of BRAFV600E gene could lead to silencing
of some thyroid-specific genes (like NIS, TG, TPO) in the activation state of
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BRAF/MEK/MAPK pathway. It could cause iodine uptake activity decrease and
ineffectiveness of radioiodine therapy. Therefore, it could affect thyroid cancer
progression.
2.4 Other potentially aberrant methylation genes in PTC
In recent years, DNA methylation has become a new research hotspot. Many
genes have been studied as potential abnormal methylation sites, including Ras
association domain family 2 (RASSF2), Ras-association domain family 10
(RASSF10), disheveled-binding antagonist of beta-catenin 2 (DACT2), retinoblas-
toma protein-interacting zinc finger gene 1 (RIZ1), 14-3-3 protein family (14-3-3
sigma), and other signaling pathways such as JAK-STAT pathway, NF-kappa B
pathway, HIF1 alpha pathway, and Notch pathway in thyroid cancer [42–45].
However, there are relatively few reports on these genes and pathways in thyroid
cancer. Most of the mechanisms are not clear at present and need further study.
3. DNA methylation in FTC
DNA methylation analysis revealed 2130 and 19 differentially methylated CpGs
in PTC and follicular thyroid carcinoma (FTC), respectively [46]. Aberrant DNA
methylation of tumor suppressor genes is common in FTC and ATC. Certain spe-
cific tumor suppressor genes are mainly PTEN, RASSF1A, Rap1-GTPase activating
protein, and thyroid-specific gene TRSH in FTC. This part summarizes the related
research on methylation genes in FTC in recent years (see Table 2).
References Gene Function DNA
methylation
BRAFE Incidence%
Tumor suppressor genes
[39–42] RASSFIA RASSF1A localizes to microtubules and
promotes their stabilization
↑ + 75% of FTC
[50] RAP1GAP RAP1GAPase-activating protein ↑ + 38% of FTC
[25] PTEN PTEN is involved in the regulation of cell
cycle and preventing cells from growing and
dividing rapidly
↑ + 85.7% of FTC
Thyroid-specific genes
[58] NIS Sodium transporter ↑ + 53.8% of
thyroid cancers
[58] TSHR Thyrotropin receptor ↑ + 47% of FTC
Oncogene genes
[52, 53] Maspin A member of serine protease inhibitor ↑ + 100% of
WDTC
Other genes
[61] DMCpG — ↑ — 84% of FTC
[61] RASAL1 — ↑ — 4.88% of FTC
[57] COL4A2 — ↑ — 56% of FTC
[64] RASSF10 — ↑ — 50% of FTC
Table 2.
Aberrant methylated genes in FTC.
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3.1 DNA methylation of tumor suppressor genes in FTC
3.1.1 PTEN
PTEN negatively regulates AKT/PKB signaling pathway. It is involved in regu-
lation of cell cycle, cell growth inhibition, and rapid division [47]. Aberrant DNA
methylation in this gene is also mostly reported in FTC. It confirmed that PTEN
promoter hypermethylation was detected in six of seven (85%) FTC and five of six
(83.3%) follicular adenomas. The results showed a high frequency of PTEN pro-
moter hypermethylation, especially in follicular tumors. It means that it has a
possible role in thyroid cancer [25]. Studies found methylation status of PTEN in FA
and FTC. And PTEN methylation level was gradually increased in FA (83.3%) and
FTC (85.7%). Authors have shown that methylation of PTEN promoter plays an
important role in FTC [48].
3.1.2 RASSF1A
Differential expression of RASSF1A gene is related to occurrence of thyroid
cancer. Aberrant DNA methylation is an important mechanism of RASSF1A gene
inactivation. Studies found 44% benign adenomas, 75% follicular thyroid cancers
tumors, and 20% PTC tumors harbored promoter methylation in greater than or
equal to 25% of RASSF1A alleles by real-time quantitative methylation-specific PCR
[39–42]. Methylation frequency was higher in invasive thyroid cancer. It was found
to be 70% of the RASSF1A methylation rate in FTC, 80% in MTC, and 78% in UTC
compared with benign PTC [14]. Inactivation of RASSF1A in different stages of
thyroid cancer was detected by tumor metastasis classification, and compared with
FTC, only a small part of RASSF1A methylation in PTC is abnormal. These studies
indicated follicular cell-derived thyroid tumorigenesis may be an early step [15, 49].
3.1.3 Rap1-GTPase-activating protein
RAP1GAP gene encodes a type of GTPase-activating protein that downregulates
Ras-related protein activity. Ras oncoproteins are very important for both develop-
ment and maintenance of many tumor types. RAP1GAP is involved in the regula-
tion of mitosis and carcinogenesis in thyroid cells. Researchers aimed to determine
the global patterns of aberrant DNA methylation in thyroid cancer using DNA
methylation arrays [50]. And the study identified 262 and 352 hypermethylated and
13 and 21 hypomethylated genes in PTC and FTC, respectively. In addition, 86 and
131 hypermethylated genes were identified. Among these genes, four potential
oncogenes (INSL4, DPPA2, TCL1B, and NOTCH4) were frequently regulated by
aberrant methylation in primary thyroid tumors [51].
3.1.4 Mammary serine protease inhibitor (Maspin)
Besides, a member of the serine protease inhibitor superfamily named Maspin is
a unique tumor suppressor gene encoding SERPINB5 gene. Epigenetic changes of
Maspin expression occurred in the 50 regulatory region of Maspin gene and involved
cytosine methylation, histone deacetylation, and chromatin accessibility. The epi-
genetic deregulation frequently participates in tumorigenesis by inactivation of
tumor suppressor genes. The association of promoter hypermethylation and gene
silencing is an established oncogenic process in cancer. Promoter methylation of
Maspin gene could lead to gene silencing in thyroid cancer, breast cancer, skin
cancer, and colon cancer. Studies have indicated that overexpression of Maspin in
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gastric cancer, pancreatic cancer, and ovarian cancers resulted from CpG promoter
of Maspin demethylation. A study detected DNA methylation status in Maspin
promoter region, indicating that overexpression of the gene was the result of DNA
hypomethylation [52]. It was closely related to the morphological dedifferentiation
of thyroid cancer. Another study found 100%Maspin hypermethylation was closely
associated with morphological dedifferentiation in thyroid cancers [52, 53].
3.2 DNA methylation of thyroid-specific genes in FTC
In addition to tumor suppressor genes and oncogenes, hypermethylation could
lead to NIS and TSHR gene silencing in FTC, too. NIS methylation is of great
significance in treatment of thyroid cancer. Therefore, abnormal methylation of
these genes may be the pathogenesis or progression factor in FTC [54, 55]. Aberrant
promoter methylation was examined in 24 tumor suppressor genes using
methylation-specific multiplex ligation-dependent probe amplification (MS-
MLPA) assay and methylation-specific PCR (MSP). In thyroid cancers, CASP8
(caspase-8), RASSF1, and NIS were methylated in 9/13, 10/13, and 7/13, respec-
tively [56]. Some researches also found combination gene panels TPO and UCHL1
(ROC = 0.607, sensitivity 78%) discriminated FTC from FA and RASSF1 and TPO
(ROC = 0.881, sensitivity 78%) discriminated FTC from normal. Methylation of
TSHR distinguished PTC from FTC (ROC = 0.701, sensitivity 84%) and PTC from
FA (ROC = 0.685, sensitivity 70%) [57]. And the six-gene panel of TIMP3, RARβ2,
SERPINB5, RASSF1, TPO, and TSHR, which differentiates PTC from normal thy-
roid, had the best combination sensitivity (91%) and specificity (81%) of the panels
addressing discrimination of cancer tissue by quantitative methylation-specific
polymerase chain reaction (QMSP) in a retrospective cohort of 329 patients [58, 59].
3.3 Other abnormal methylation genes in FTC
Nowadays, there are a few studies on methylation of FTC genes. However, many
genes still have been studied as potential abnormal methylation sites in FTC. For
example, one of the ZIC families called ZIC1 (C2H2-type zinc finger proteins) is
frequently hypermethylated in FTCs [60]. Moreover, 3564 differentially methyl-
ated CpGs (DMCpG) were detected in FTC and 84% hypermethylated with respect
to normal controls. It is suggested that perturbed DNA methylation, in particular
hypermethylation, is a component of the molecular mechanisms leading to FTC
formation and that DNA methylation profiling might help in differentiating FTCs
from their benign counterpart [61]. Also, others identified the presence of RASAL1
mutations, with a prevalence of 4.88% (n = 2 of 41) in FTC and 16.67% (n = 5 of 30)
in ATC [62]. Studies found a more detailed analysis showing that 53.9% of the
hypermethylated and 81.5% of the hypomethylated CpG sites identified in differ-
entiated primary tumors (PTCs and FTCs) were also present in differentiated
thyroid carcinoma-derived cancer cell [61]. Aside from that, COL4A2 was
hypermethylated in 56% of the FTC samples by array measurement in the discovery
series [57, 63]. Another study indicated that RASSF10 was frequently
hypermethylated in thyroid cancer. It showed 50% of methylation frequency of
RASSF10 in FTC and the highest (100%) in MTCs [64].
4. DNA methylation in ATC
Promoter methylation of PTEN is also common in anaplastic thyroid cancer
(ATC) [65]. PTEN methylation is related to gene changes of PI3K Akt pathway in
10
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thyroid tumors, including PTEN mutations, various subtypes of Ras mutations,
PIK3CA mutations, and amplification [66, 67]. One study analyzed 24 genetic
alterations in the major genes of MAPK and PI3K-AKT pathways in 48 ATC samples
and found that the majority of (81%) samples that harbored genetic alterations
could be likely activated in both pathways [68]. Accordingly, another DNA meth-
ylation pan-cancer study focused on promoters found that thyroid carcinoma
exhibited one of the lowest frequencies in both hypomethylation and
hypermethylation events. And ATC exhibits a high frequency of DNA methylation
alterations (tenfold higher than PTC) [69, 70]. A recent pan-cancer analysis on
whole exome sequencing revealed that the mutation frequency in PTC was one of
the lowest (approximately 1 change/Mb across the entire exome) among solid
tumors, while the mutation frequency in ATC was at the opposite extreme and was
closer to that in melanoma and lung cancer, exceeding 100 changes/Mb [71, 72].
In addition, solute carrier family 26, member 4 (SLC26A4) gene, encodes a
transmembrane protein named pendrin with up to 15 predicted membrane span-
ning domains and affects the flow of iodine into follicular lumen. The following
were reported: 71% of ATC, 44% of benign tumors, 46% of FTC, and 71% of PTC,
with abnormal SLC26A4 gene methylation in 64 cases of primary thyroid tumors
and 6 cases of thyroid tumor cell lines [18, 73]. In addition, 81.5% of
hypermethylated genes and 89% of hypomethylated genes were also present in
nondifferentiated primary tumors (MTCs and ATCs) and nondifferentiated thyroid
carcinoma-derived cancer cell lines [74], while Ras protein activator like-1 gene
(RASAL1) displayed MAPK- and PI3K-suppressing and thyroid tumor-suppressing
activities, which can be impaired by the mutations. Hypermethylation and muta-
tions of RASAL1 were found in 33.33% (n = 10 of 30) of ATCs and in 0 of 20 (0%)
of benign thyroid tumors [62]. However, ATC showed more hypomethylation than
hypermethylation events, indicating that hypomethylation is related to dedifferen-
tiation [70]. The authors validated four genes (NOTCH4 and TCL1B in ATCs,
INSL4 and DPPA2 in MTCs) that become aberrantly hypomethylated in nondiffer-
entiated thyroid tumors. All of them have been proposed to have an oncogenic role
in cancer. And NOTCH4 (a member of the Notch family of transmembrane recep-
tors) is frequently overexpressed in thyroid tumors [75, 76].
This part summarizes the related research on methylation genes in ATC in
recent years (see Table 3).
Authors Gene Function DNA
methylation
BRAFE Incidence%
Oncogene genes
[70] TCL1B An oncogene frequently activated
by reciprocal translocations
↑ + 64% of ATC
[70] NOTCH4 A Member of notch family, which
plays a role in a variety of
developmental processes
↑ + 45% of ATC
Thyroid-specific genes
[18, 73] SLC26A4 Dysfunctional pendrin ↑ — 71% ATC
Tumor suppressor genes
[25] PTEN PI3K–AKT pathway ↑ — 81% of ATC
[62] RASAL1 MAPK- and PI3K-suppressing ↑ — 33.33% of ATC
Table 3.
Aberrant methylated genes in ATC.
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5. DNA methylation in MTC
Medullary thyroid cancer is a neuroendocrine tumor originating from
parafollicular C cells, and it is highly resistant to chemo- and radiotherapy [77].
Spry1 is a candidate tumor-suppressor gene in MTC. The hyper-activation of PI3K/
Akt/mTOR cascade has a relevant role in the pathogenesis and progression of MTC.
In fact, most of pro-oncogenic effects of RET and Ras mutations are modulated by
the activation of PI3K/Akt/mTOR pathway [78, 79]. For patients with metastatic
disease, standard treatment modalities include local treatments (radiofrequency
ablation, radiation therapy, embolization) and systemic treatment chemotherapy
and more recently tyrosine kinase inhibitors (TKIs) targeting RET protein. As
experience has been limited to case reports or case series, response rates (RR)
ranged from 0 to 25% for periods of up to a few months. In nondifferentiated
thyroid tumors, INSL4 and DPPA2 become aberrantly hypomethylated, both of
which have been proposed to have an oncogenic role in MTC.
5.1 Sprouty1 (Spry1)
Sprouty (Spry) family of genes is composed of four members in mammals
(Spry1–4). The Spry1 promoter is frequently methylated in MTC, and that Spry1
expression is consequently decreased. These findings identify Spry1 as a candidate
tumor-suppressor gene in MTC. In mammals, the situation is more complicated as
Spry proteins have been shown to be activators or inhibitors of receptor tyrosine
kinase signaling depending on the cellular context or the receptor tyrosine kinase
analyzed [80, 81]. Spry family members have been proposed to function as tumor-
suppressor genes in a growing list of cancerous malignancies, including prostate and
hepatocellular carcinoma, B-cell lymphoma, or neuroblastoma [82]. Finally, the
authors found that SPRY1 promoter is frequently methylated and its expression
decreased in human MTC. The mRNA levels of Spry1 are detected in murine C cells
of thyroid with real-time RT-PCR. In situ hybridization showed expression of Spry1
mRNA in the fourth pharyngeal pouch, where thyroid C-cells originate and beta-
galactosidase staining of thyroids from 1-month-old Spry1LacZ/þ mice. One study
used the hypomethylating agent 50-aza-deoxycytidine (50-Aza-dC) to confirm a
causal relationship between promoter methylation and Spry1 expression [83]. As
expected, TT cells treated with 50-aza-dC showed an increase of approximately
sixfold in the levels of Spry1 mRNA when compared to vehicle-treated cells.
50-Aza-deoxycytidine (AZA), a demethylating agent, is in combination with the
mTOR inhibitor everolimus in MTC cells (MZ-CRC-1 and TT). An innovative
bioinformatic pipeline identified four potential molecular pathways implicated in
the synergy between AZA and everolimus: PI3K-Akt signaling, the neurotrophin
pathway, ECM-receptor interaction, and focal adhesion. Among these, the
neurotrophin signaling pathway was most directly involved in apoptosis, through
NGFR and Bax gene overexpression. Increased expression of genes involved in the
NGFR-MAPK10-TP53-Bax/Bcl2 pathway during incubation with AZA plus
everolimus was validated by western blotting in MZ-CRC-1 cells [84].
5.2 Insulin-like 4 (INSL4)
INSL4 (pro-EPIL) belongs to the insulin and insulin-like growth factor family
and is expressed strongly during the first trimester of pregnancy by the differenti-
ated syncytiotrophoblast [85]. It has been shown to be overexpressed in breast
tumors with an aggressive phenotype [86], but the underlying mechanisms are still
12
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unknown. The aberrant overexpression of INSL4 in breast tumors, together with
the aberrant promoter hypomethylation reported in this study, suggests that pro-
moter demethylation might be a frequent mechanism of activation of INSL4 onco-
gene activation in cancer.
5.3 Developmental pluripotency-associated 2 (DPPA2)
DPPA2 is expressed early in the embryo’s development [87] but also in some
tumor types [88]. Although the underlying molecular mechanism has not been
reported yet, the authors’ data indicated that promoter hypomethylation might play
an important role. The frequent promoter hypomethylation observed in nondiffer-
entiated tumors might be relevant for treatment with demethylating drugs [51, 88].
6. Conclusion
More and more researches have realized that the occurrence of tumors is not
only entirely determined by genes but also epigenetics. The changes of epigenetics
in thyroid cancer are mainly manifested in the aberrant methylation of tumor
suppressor genes and thyroid-related genes. Numerous studies on DNAmethylation
in thyroid cancer have improved our understanding of thyroid carcinogenesis.
Some of the recent findings, including the huge catalog of DNA methylation alter-
ations, the association of DNA hypomethylation with cancer progression and
dedifferentiation, the existence of different methylomes related to different clinical
and molecular phenotypes, and the influence of immune-infiltrating cells in tumor
DNAmethylation patterns, are most likely to lead the direction of future research in
the field of DNA methylation in thyroid cancer. A large number of studies con-
firmed the importance of DNA methylation as a source of novel biomarkers for
early diagnosis, therapeutic perspective, and prognosis evaluation in thyroid cancer.
In addition, the design of specific target demethylation drugs, which reactivate the
function of tumor suppressor genes, is expected to become a new scheme for cancer
treatment. Therefore, further functional experiments in vitro and in vivo are nec-
essary for better understanding of the meaning and potential mechanism of DNA
methylation changes in thyroid cancer as well as the evaluation of candidate bio-
markers through case-control studies and prospective trials.
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